Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Highly efficient site-specific transgenesis in cancer cell lines

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

Transgenes introduced into cancer cell lines serve as powerful tools for identification of genes involved in cancer. However, the random nature of genomic integration site of a transgene highly influences the fidelity, reliability and level of its expression. In order to alleviate this bottleneck, we characterized the potential utility of a novel PhiC31 integrase-mediated site-specific insertion system (PhiC31-IMSI) for introduction of transgenes into a pre-inserted docking site in the genome of cancer cells.

Methods

According to this system, a “docking-site” was first randomly inserted into human cancer cell lines and clones with a single copy were selected. Subsequently, an “incoming” vector containing the gene of interest was specifically inserted in the docking-site using PhiC31.

Results

Using the Pc-3 and SKOV-3 cancer cell lines, we showed that transgene insertion is reproducible and reliable. Furthermore, the selection system ensured that all surviving stable transgenic lines harbored the correct integration site. We demonstrated that the expression levels of reporter genes, such as green fluorescent protein and luciferase, from the same locus were comparable among sister, isogenic clones. Using in vivo xenograft studies, we showed that the genetically altered cancer cell lines retain the properties of the parental line. To achieve temporal control of transgene expression, we coupled our insertion strategy with the doxycycline inducible system and demonstrated tight regulation of the expression of the antiangiogenic molecule sFlt-1-Fc in Pc-3 cells. Furthermore, we introduced the luciferase gene into the insertion cassette allowing for possible live imaging of cancer cells in transplantation assays. We also generated a series of Gateway cloning-compatible intermediate cassettes ready for high-throughput cloning of transgenes and demonstrated that PhiC31-IMSI can be achieved in a high throughput 96-well plate format.

Conclusions

The novel PhiC31-IMSI system described in this study represents a powerful tool that can facilitate the characterization of cancer-related genes.
Appendix
Available only for authorised users
Literature
1.
Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009, 9 (2): 95-107. 10.1038/nrc2584CrossRefPubMed
2.
Soussi T, Wiman KG: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007, 12 (4): 303-312. 10.1016/j.ccr.2007.10.001CrossRefPubMed
3.
Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA. 2009, 106 (10): 3964-3969. 10.1073/pnas.0813333106PubMedCentralCrossRefPubMed
4.
Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S: Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta. 2004, 1705 (2): 103-120.PubMed
5.
Recillas-Targa F: Multiple strategies for gene transfer, expression, knockdown, and chromatin influence in mammalian cell lines and transgenic animals. Mol Biotechnol. 2006, 34 (3): 337-354. 10.1385/MB:34:3:337CrossRefPubMed
6.
Soriano P: Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999, 21 (1): 70-71. 10.1038/5007CrossRefPubMed
7.
Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A: Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 2005, 33 (5): e51- 10.1093/nar/gni051PubMedCentralCrossRefPubMed
8.
Thompson S, Clarke AR, Pow AM, Hooper ML, Melton DW: Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells. Cell. 1989, 56 (2): 313-321. 10.1016/0092-8674(89)90905-7CrossRefPubMed
9.
Sakurai K, Shimoji M, Tahimic CG, Aiba K, Kawase E, Hasegawa K, Amagai Y, Suemori H, Nakatsuji N: Efficient integration of transgenes into a defined locus in human embryonic stem cells. Nucleic Acids Res. 2010, 38 (7): e96- 10.1093/nar/gkp1234PubMedCentralCrossRefPubMed
10.
Sorrell DA, Kolb AF: Targeted modification of mammalian genomes. Biotechnol Adv. 2005, 23 (7–8): 431-469.CrossRefPubMed
11.
Kolb AF: Genome engineering using site-specific recombinases. Cloning Stem Cells. 2002, 4 (1): 65-80. 10.1089/153623002753632066CrossRefPubMed
12.
Branda CS, Dymecki SM: Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell. 2004, 6 (1): 7-28. 10.1016/S1534-5807(03)00399-XCrossRefPubMed
13.
Belteki G, Gertsenstein M, Ow DW, Nagy A: Site-specific cassette exchange and germline transmission with mouse ES cells expressing phiC31 integrase. Nat Biotechnol. 2003, 21 (3): 321-324. 10.1038/nbt787CrossRefPubMed
14.
van der Weyden L, Adams DJ, Bradley A: Tools for targeted manipulation of the mouse genome. Physiol Genomics. 2002, 11 (3): 133-164.CrossRefPubMed
15.
Vasquez KM, Marburger K, Intody Z, Wilson JH: Manipulating the mammalian genome by homologous recombination. Proc Natl Acad Sci USA. 2001, 98 (15): 8403-8410. 10.1073/pnas.111009698PubMedCentralCrossRefPubMed
16.
Irion S, Luche H, Gadue P, Fehling HJ, Kennedy M, Keller G: Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol. 2007, 25 (12): 1477-1482. 10.1038/nbt1362CrossRefPubMed
17.
Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 1993, 9 (4): 138-141. 10.1016/0168-9525(93)90209-ZCrossRefPubMed
18.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature. 1998, 396 (6712): 643-649. 10.1038/25292CrossRefPubMed
19.
Rago C, Vogelstein B, Bunz F: Genetic knockouts and knockins in human somatic cells. Nat Protoc. 2007, 2 (11): 2734-2746. 10.1038/nprot.2007.408CrossRefPubMed
20.
Porteus M: Using homologous recombination to manipulate the genome of human somatic cells. Biotechnol Genet Eng Rev. 2007, 24: 195-212.CrossRefPubMed
21.
Kim JS, Bonifant C, Bunz F, Lane WS, Waldman T: Epitope tagging of endogenous genes in diverse human cell lines. Nucleic Acids Res. 2008, 36 (19): e127- 10.1093/nar/gkn566PubMedCentralCrossRefPubMed
22.
Hoess RH, Ziese M, Sternberg N: P1 site-specific recombination: nucleotide sequence of the recombining sites. Proc Natl Acad Sci USA. 1982, 79 (11): 3398-3402. 10.1073/pnas.79.11.3398PubMedCentralCrossRefPubMed
23.
Hamilton DL, Abremski K: Site-specific recombination by the bacteriophage P1 lox-Cre system. Cre-mediated synapsis of two lox sites. J Mol Biol. 1984, 178 (2): 481-486. 10.1016/0022-2836(84)90154-2CrossRefPubMed
24.
Kilby NJ, Snaith MR, Murray JA: Site-specific recombinases: tools for genome engineering. Trends Genet. 1993, 9 (12): 413-421. 10.1016/0168-9525(93)90104-PCrossRefPubMed
25.
Bode J, Schlake T, Iber M, Schubeler D, Seibler J, Snezhkov E, Nikolaev L: The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes. Biol Chem. 2000, 381 (9–10): 801-813.PubMed
26.
Nagy A: Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000, 26 (2): 99-109. 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-BCrossRefPubMed
27.
Baer A, Bode J: Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. Curr Opin Biotechnol. 2001, 12 (5): 473-480. 10.1016/S0958-1669(00)00248-2CrossRefPubMed
28.
Zhang Z, Lutz B: Cre recombinase-mediated inversion using lox66 and lox71: method to introduce conditional point mutations into the CREB-binding protein. Nucleic Acids Res. 2002, 30 (17): e90- 10.1093/nar/gnf089PubMedCentralCrossRefPubMed
29.
Oberdoerffer P, Otipoby KL, Maruyama M, Rajewsky K: Unidirectional Cre-mediated genetic inversion in mice using the mutant loxP pair lox66/lox71. Nucleic Acids Res. 2003, 31 (22): e140- 10.1093/nar/gng140PubMedCentralCrossRefPubMed
30.
Wong ET, Kolman JL, Li YC, Mesner LD, Hillen W, Berens C, Wahl GM: Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange. Nucleic Acids Res. 2005, 33 (17): e147- 10.1093/nar/gni145PubMedCentralCrossRefPubMed
31.
Warren D, Laxmikanthan G, Landy A: A chimeric Cre recombinase with regulated directionality. Proc Natl Acad Sci USA. 2008, 105 (47): 18278-18283. 10.1073/pnas.0809949105PubMedCentralCrossRefPubMed
32.
Rausch H, Lehmann M: Structural analysis of the actinophage phi C31 attachment site. Nucleic Acids Res. 1991, 19 (19): 5187-5189. 10.1093/nar/19.19.5187PubMedCentralCrossRefPubMed
33.
Thorpe HM, Smith MC: In vitro site-specific integration of bacteriophage DNA catalyzed by a recombinase of the resolvase/invertase family. Proc Natl Acad Sci USA. 1998, 95 (10): 5505-5510. 10.1073/pnas.95.10.5505PubMedCentralCrossRefPubMed
34.
Thorpe HM, Wilson SE, Smith MC: Control of directionality in the site-specific recombination system of the Streptomyces phage phiC31. Mol Microbiol. 2000, 38 (2): 232-241. 10.1046/j.1365-2958.2000.02142.xCrossRefPubMed
35.
Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT, Hoelters J, Calos MP: Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol. 2006, 357 (1): 28-48. 10.1016/j.jmb.2005.11.098CrossRefPubMed
36.
Groth AC, Olivares EC, Thyagarajan B, Calos MP: A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA. 2000, 97 (11): 5995-6000. 10.1073/pnas.090527097PubMedCentralCrossRefPubMed
37.
Thyagarajan B, Guimaraes MJ, Groth AC, Calos MP: Mammalian genomes contain active recombinase recognition sites. Gene. 2000, 244 (1–2): 47-54.CrossRefPubMed
38.
Thyagarajan B, Liu Y, Shin S, Lakshmipathy U, Scheyhing K, Xue H, Ellerström C, Strehl R, Hyllner J, Rao MS: Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells. 2008, 26 (1): 119-126. 10.1634/stemcells.2007-0283CrossRefPubMed
39.
Monetti C, Nishino K, Biechele S, Zhang P, Baba T, Woltjen K, Nagy A: PhiC31 integrase facilitates genetic approaches combining multiple recombinases. Methods. 2011, 53 (4): 380-385. 10.1016/j.ymeth.2010.12.023CrossRefPubMed
40.
Szymczak AL, Vignali DAA: Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther. 2005, 5 (5): 627-638. 10.1517/14712598.5.5.627CrossRefPubMed
41.
Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT: Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med. 2004, 6 (7): 817-828. 10.1002/jgm.566CrossRefPubMed
42.
Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA. 2000, 97 (14): 7963-7968. 10.1073/pnas.130192197PubMedCentralCrossRefPubMed
43.
Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993, 90 (22): 10705-10709. 10.1073/pnas.90.22.10705PubMedCentralCrossRefPubMed
44.
Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem. 1997, 272 (16): 10382-10388. 10.1074/jbc.272.16.10382CrossRefPubMed
45.
46.
Schubeler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, Bouhassira EE, Groudine M: Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol. 2000, 20 (24): 9103-9112. 10.1128/MCB.20.24.9103-9112.2000PubMedCentralCrossRefPubMed
47.
Feng YQ, Lorincz MC, Fiering S, Greally JM, Bouhassira EE: Position effects are influenced by the orientation of a transgene with respect to flanking chromatin. Mol Cell Biol. 2001, 21 (1): 298-309. 10.1128/MCB.21.1.298-309.2001PubMedCentralCrossRefPubMed
48.
Feng YQ, Alami R, Bouhassira EE: Enhancer-dependent transcriptional oscillations in mouse erythroleukemia cells. Mol Cell Biol. 1999, 19 (7): 4907-4917.PubMedCentralPubMed
49.
Feng YQ, Warin R, Li T, Olivier E, Besse A, Lobell A, Fu H, Lin CM, Aladjem MI, Bouhassira EE: The human beta-globin locus control region can silence as well as activate gene expression. Mol Cell Biol. 2005, 25 (10): 3864-3874. 10.1128/MCB.25.10.3864-3874.2005PubMedCentralCrossRefPubMed
Metadata
Title
Highly efficient site-specific transgenesis in cancer cell lines
Publication date
01-12-2012
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-89

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

Research

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

Research

A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line

Research

Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression

Research

Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma

Research

Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits